Alternative molecular formats and therapeutic applications for bispecific antibodies.
暂无分享,去创建一个
[1] L. Presta,et al. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. , 1996, Protein engineering.
[2] B. Robert,et al. Radiocurability by targeting tumor necrosis factor-alpha using a bispecific antibody in carcinoembryonic antigen transgenic mice. , 2007, International journal of radiation oncology, biology, physics.
[3] W. Mcbride,et al. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. , 2010, Seminars in nuclear medicine.
[4] L. Presta,et al. Remodeling domain interfaces to enhance heterodimer formation , 1997, Protein science : a publication of the Protein Society.
[5] D. Ecker,et al. The therapeutic monoclonal antibody market , 2015, mAbs.
[6] F. Marmé,et al. Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites , 2011, International journal of cancer.
[7] Jack Bevers,et al. Development of a Human IgG4 Bispecific Antibody for Dual Targeting of Interleukin-4 (IL-4) and Interleukin-13 (IL-13) Cytokines* , 2013, The Journal of Biological Chemistry.
[8] G. Schaefer,et al. LUZ-Y, a Novel Platform for the Mammalian Cell Production of Full-length IgG-bispecific Antibodies* , 2012, The Journal of Biological Chemistry.
[9] J. Wells,et al. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. , 1997, Journal of molecular biology.
[10] W. Mcbride,et al. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[11] Diego Ellerman,et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies , 2013, Nature Biotechnology.
[12] Yang Yang,et al. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. , 2015, Cancer research.
[13] M. Mack,et al. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[14] Chien-Hsing Chang,et al. The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity , 2007, Clinical Cancer Research.
[15] Leonard A. Smith,et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[16] R. Kontermann,et al. Dual targeting strategies with bispecific antibodies , 2012, mAbs.
[17] Garrett M. Morris,et al. Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design , 2001, Science.
[18] S. Kadono,et al. Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant , 2013, mAbs.
[19] P. Baeuerle,et al. Targeting T cells to tumor cells using bispecific antibodies. , 2013, Current opinion in chemical biology.
[20] Michaela A. E. Arndt,et al. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors. , 1999, Blood.
[21] Sahana Bose,et al. Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. , 2009, mAbs.
[22] J. Zenilman,et al. Safety and Pharmacokinetics of XOMA 3AB, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin A , 2014, Antimicrobial Agents and Chemotherapy.
[23] Herren Wu,et al. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. , 2009, Journal of molecular biology.
[24] F. Kreutz,et al. A new method to generate quadromas by electrofusion and FACS sorting. , 1998, Hybridoma.
[25] H. Einsele,et al. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.
[26] P. S. Andersen,et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor , 2011, mAbs.
[27] P. Moore,et al. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. , 2010, Journal of molecular biology.
[28] Anirvan Ghosh,et al. Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle , 2014, Neuron.
[29] John Kelly,et al. Improving biophysical properties of a bispecific antibody scaffold to aid developability , 2013, mAbs.
[30] J. Eldredge,et al. A novel platform for engineering blood‐brain barrier‐crossing bispecific biologics , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[31] P. Parren,et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo , 2009, Nature Biotechnology.
[32] Andreas Plückthun,et al. Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs. , 2014, Current opinion in structural biology.
[33] B. Jakobsen,et al. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells , 2014, Cancer Immunology, Immunotherapy.
[34] W. Luk,et al. Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target , 2011, Science Translational Medicine.
[35] T Prospero,et al. "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[36] R. Kontermann,et al. Strategies for extended serum half-life of protein therapeutics. , 2011, Current opinion in biotechnology.
[37] Michael J. Gramer,et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange , 2013, Proceedings of the National Academy of Sciences.
[38] G. A. Lazar,et al. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens , 2011, mAbs.
[39] Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene , 1992, The Journal of experimental medicine.
[40] J. Reichert,et al. World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA , 2012, mAbs.
[41] A. Nisonoff,et al. Recombination of a mixture of univalent antibody fragments of different specificity. , 1961, Archives of biochemistry and biophysics.
[42] P. Bohlen,et al. Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody* , 2004, Journal of Biological Chemistry.
[43] Andrew Leaver-Fay,et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface , 2014, Nature Biotechnology.
[44] Paul J Conroy,et al. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications , 2013, Trends in Biotechnology.
[45] P. T. Jones,et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli , 1989, Nature.
[46] R. Bruccoleri,et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[47] G. Winter,et al. Retargeting serum immunoglobulin with bispecific diabodies , 1997, Nature Biotechnology.
[48] J. Kremer,et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial , 2006, Annals of the rheumatic diseases.
[49] Peter Bohlen,et al. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. , 2001, Cancer research.
[50] Tsukasa Suzuki,et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model , 2012, Nature Medicine.
[51] R. Lerner,et al. Chemical generation of bispecific antibodies , 2010, Proceedings of the National Academy of Sciences.
[52] M. Glennie,et al. Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments. , 1987, Journal of immunology.
[53] J. Chon,et al. Advances in the production and downstream processing of antibodies. , 2011, New biotechnology.
[54] C. R. Leemans,et al. Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology , 2008, Molecular Cancer Therapeutics.
[55] Lawren C. Wu,et al. Development of a Two-part Strategy to Identify a Therapeutic Human Bispecific Antibody That Inhibits IgE Receptor Signaling* , 2010, The Journal of Biological Chemistry.
[56] I. Tomlinson,et al. Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. , 2007, The Journal of infectious diseases.
[57] R. Watts,et al. Bispecific antibodies for delivery into the brain. , 2013, Current opinion in chemical biology.
[58] G. V. Vande Woude,et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent , 2013, Proceedings of the National Academy of Sciences.
[59] R. Kontermann,et al. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. , 2007, Protein engineering, design & selection : PEDS.
[60] R. Kontermann,et al. Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin* , 2007, Journal of Biological Chemistry.
[61] Lode Wyns,et al. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme , 1996, Nature Structural Biology.
[62] J. Marvin,et al. Recombinant approaches to IgG-like bispecific antibodies , 2005, Acta Pharmacologica Sinica.
[63] C. Klein,et al. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. , 2012, Archives of biochemistry and biophysics.
[64] Самьюэл Дэвис,et al. Readily isolated bispecific antibodies with native immunoglobulin format , 2010 .
[65] Brian Kelley,et al. Industrialization of mAb production technology: The bioprocessing industry at a crossroads , 2009, mAbs.
[66] Fredrik Y Frejd,et al. Engineering and characterization of a bispecific HER2 × EGFR‐binding affibody molecule , 2009, Biotechnology and applied biochemistry.
[67] D. Goldenberg,et al. A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells. , 2010, Cancer research.
[68] Chien-Hsing Chang,et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody , 2005, Nature Medicine.
[69] Gary Walsh,et al. Biopharmaceutical benchmarks 2014 , 2014, Nature Biotechnology.
[70] B. Sandmaier,et al. Contributions of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency. , 1998, Biophysical journal.
[71] D. Chelius,et al. Structural and functional characterization of the trifunctional antibody catumaxomab , 2010, mAbs.
[72] D. Hicklin,et al. A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity* , 2005, Journal of Biological Chemistry.
[73] T. Igawa,et al. Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity , 2013, PloS one.
[74] C. Klein,et al. A Novel Glycoengineered Bispecific Antibody Format for Targeted Inhibition of Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor Receptor Type I (IGF-1R) Demonstrating Unique Molecular Properties* , 2014, The Journal of Biological Chemistry.
[75] U. Brinkmann,et al. Bispecific digoxigenin-binding antibodies for targeted payload delivery , 2011, Proceedings of the National Academy of Sciences.
[76] M. Wittekind,et al. Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects , 2010, The Journal of Biological Chemistry.
[77] Andrew C. Chan,et al. Therapeutic antibodies for autoimmunity and inflammation , 2010, Nature Reviews Immunology.
[78] Sahana Bose,et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin , 2007, Nature Biotechnology.
[79] E. Remaut,et al. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. , 2006, Arthritis and rheumatism.
[80] G. Riethmüller. Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. , 2012, Cancer immunity.
[81] M. Pfreundschuh,et al. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. , 1997, Blood.
[82] A. Plückthun,et al. Bispecific Designed Ankyrin Repeat Proteins (DARPins) Targeting Epidermal Growth Factor Receptor Inhibit A431 Cell Proliferation and Receptor Recycling* , 2011, The Journal of Biological Chemistry.
[83] C. Jakob,et al. Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule , 2013, mAbs.
[84] P. Murawa,et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial , 2010, International journal of cancer.
[85] Guy Georges,et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies , 2011, Proceedings of the National Academy of Sciences.
[86] G. Denardo,et al. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility. , 2006, Journal of immunological methods.
[87] P. Tessier,et al. Engineering aggregation-resistant antibodies. , 2012, Annual review of chemical and biomolecular engineering.
[88] X. Qiu,et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb , 2013, Scientific Reports.
[89] K. Scearce-Levie,et al. Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier , 2013, Science Translational Medicine.
[90] P. Parren,et al. Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange , 2007, Science.
[91] M. Vogel,et al. DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage. , 2009, Journal of molecular biology.
[92] Scott R. Presnell,et al. Engineering of stable bispecific antibodies targeting IL-17A and IL-23. , 2009, Protein engineering, design & selection : PEDS.
[93] Gary Walsh,et al. Biopharmaceutical benchmarks , 2000, Nature Biotechnology.
[94] Rutilio H. Clark,et al. A Novel Antibody Engineering Strategy for Making Monovalent Bispecific Heterodimeric IgG Antibodies by Electrostatic Steering Mechanism* , 2015, The Journal of Biological Chemistry.
[95] Osami Kanagawa,et al. Hybrid antibodies can target sites for attack by T cells , 1985, Nature.
[96] J. Huston,et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. , 2010, Protein engineering, design & selection : PEDS.
[97] S E Hufton,et al. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains. , 2001, Journal of molecular biology.
[98] L. Wyns,et al. Camel Single-domain Antibodies as Modular Building Units in Bispecific and Bivalent Antibody Constructs* , 2001, The Journal of Biological Chemistry.
[99] M. Little,et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. , 1999, Journal of molecular biology.
[100] Henrik Næsted,et al. Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use , 2011, Biotechnology and bioengineering.
[101] Martin C. Wright,et al. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor , 2011, mAbs.
[102] Camellia W. Adams,et al. An efficient route to human bispecific IgG , 1998, Nature Biotechnology.
[103] Franklin Peale,et al. Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site , 2009, Science.
[104] L. Weiner,et al. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. , 1995, Cancer research.
[105] K Dane Wittrup,et al. A modular IgG-scFv bispecific antibody topology. , 2010, Protein engineering, design & selection : PEDS.
[106] T. Igawa,et al. VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody. , 2010, Protein engineering, design & selection : PEDS.
[107] M. Little,et al. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation. , 2000, Cancer research.
[108] S. Akilesh,et al. FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.
[109] P F Davison,et al. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. , 1985, Science.
[110] C. Klein,et al. Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable Domain , 2013, PloS one.
[111] L. Weiner,et al. Phase I Trial of 2B1, a Bispecific Monoclonal Antibody Targeting c-erbB-2 and FcγRIII , 1995 .
[112] M R Suresh,et al. Advantages of bispecific hybridomas in one-step immunocytochemistry and immunoassays. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[113] C. Barbas,et al. Chemically programmed antibodies: endothelin receptor targeting CovX-Bodies. , 2007, Bioorganic & medicinal chemistry letters.
[114] B. Carragher,et al. The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen , 2013, mAbs.
[115] P. Kufer,et al. Blinatumomab: a historical perspective. , 2012, Pharmacology & therapeutics.
[116] S. Bregenholt,et al. Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections. , 2006, Current pharmaceutical design.
[117] Scott M Glaser,et al. Antibody therapeutics, antibody engineering, and the merits of protein stability. , 2008, Current opinion in drug discovery & development.
[118] K. D. Hardman,et al. Single-chain antigen-binding proteins. , 1988, Science.
[119] R. Kontermann,et al. Novel tetravalent and bispecific IgG‐like antibody molecules combining single‐chain diabodies with the immunoglobulin γ1 Fc or CH3 region , 1999, FEBS letters.
[120] Pavel Strop,et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. , 2012, Journal of molecular biology.
[121] B. Jakobsen,et al. ImmTACs: Novel bi-specific agents for targeted cancer therapy. , 2013, Oncoimmunology.
[122] D. Goldenberg,et al. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. , 2009, Blood.
[123] David Baker,et al. Macromolecular modeling with rosetta. , 2008, Annual review of biochemistry.
[124] M. Sliwkowski,et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. , 2011, Cancer cell.
[125] Andrew Burnette,et al. Monoclonal antibody therapeutics with up to five specificities , 2013, mAbs.
[126] M. Suresh,et al. Sequential affinity purification of peroxidase tagged bispecific anti-SARS-CoV antibodies on phenylboronic acid agarose , 2008, Journal of Chromatography B.
[127] L. Riechmann,et al. Antibody VH Domains as Small Recognition Units , 1995, Bio/Technology.